Orwa Aboud is a Neurology physician. OpenAlex indexes 127 publications with 582 citations (h-index 12); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
201 N Broadway St
Baltimore, MD 212870031
Telephone
501-786-9272Provider last certified this registry record 23 Apr 2020.
Clinical trials
- Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
Sponsor: University of California, Davis
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Alexion Pharmaceuticals, Inc.Program year20251 payment
- SERVIER PHARMACEUTICALS LLCProgram year20236 payments
- Merck Sharp & Dohme LLCProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
46.7%Other antiepileptics25.8%Levetiracetam63%Lacosamide37%Part D<11 patientsGabapentinoids11.3%Gabapentin62%Pregabalin38%Part D<11 patients+ 2 more classes in this area
Cancer & immunology
17.5%Kinase inhibitor13.6%Everolimus63%Koselugo37%Part D<11 patientsHypoxia-inducible Factor Inhibitor4%Welireg100%Part D<11 patientsSensory organs
14.2%Corticosteroid14.2%Dexamethasone100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Clinical Value of ChatGPT for Epilepsy Presurgical Decision-Making: Systematic Evaluation of Seizure Semiology Interpretation
Journal of Medical Internet Research
2025 - A novel predictive model utilizing retinal microstructural features for estimating survival outcome in patients with glioblastoma
Clinical Neurology and Neurosurgery
2025 - Serendipity in Neuro-Oncology: The Evolution of Chemotherapeutic Agents
International Journal of Molecular Sciences
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”